Daprodustat: First Approval

Link to article at PubMed

Drugs. 2020 Sep 3. doi: 10.1007/s40265-020-01384-y. Online ahead of print.


Daprodustat (DUVROQ) is a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (PHD) developed by GlaxoSmithKline for the treatment of anaemia in patients with chronic kidney disease (CKD). Inhibition of PHD prevents degradation of hypoxia-inducible factor (HIF), leading to the production of erythropoietin and subsequent induction of erythropoiesis. In June, daprodustat received its first approval in Japan for the treatment of renal anaemia. Clinical studies of daprodustat are underway in multiple countries worldwide. This article summarizes the milestones in the development of daprodustat leading to this first approval for the treatment of renal anaemia.

PMID:32880805 | DOI:10.1007/s40265-020-01384-y

Leave a Reply

Your email address will not be published. Required fields are marked *